TITLE

DEBIOPHARM TO CONTINUE BRAINZ STUDY WITH DEBIO 9902 SR

PUB. DATE
April 2008
SOURCE
Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that global independent biopharmaceutical company Debiopharm Group in Lausanne, Switzerland, has received a recommendation to continue its Phase II BRAINz study with Debio 9902 sustained release (SR) for the treatment of Alzheimer's disease without modification. According to David Wilkinson of Moorgreen Hospital, the recommendation confirms the safety profile of Debio 9902 SR, a novel acetylcholinesterase (AChE) inhibitor.
ACCESSION #
31446988

 

Related Articles

  • Debiopharm and Pharmaleads sign licensing agreement.  // PharmaWatch: Biotechnology;Jan2009, Vol. 8 Issue 1, p17 

    The article reports on an exclusive license agreement signed by Debiopharm Group for the development, registration and commercialization of a small molecule called Debio 0827 or PL37 in the U.S. The agreement allows Debiopharm to make an up-front payment to Pharmaleads. It is revealed that Debio...

  • Regular Use of Acetylcholinesterase Inhibitors, Memantine Linked to Reduced Mortality in Alzheimer's Disease. Hughes, Debra // Neurology Reviews;Aug2007, Vol. 15 Issue 8, p58 

    The article presents a study which investigates the correlation between the use of acetylcholinesterase inhibitors and memantine and the mortality rate in Alzheimer's disease. Randomize clinical trials of acetylcholinesterase inhibitors and memantine have showed efficacy for maintaining or...

  • Donepezil: A Review of Pharmacological Characteristics and Role in the Management of Alzheimer Disease. Jelic, Vesna; Darreh-Shori, Taher // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p771 

    Donepezil is a potent, selective, noncompetitive, and rapidly reversible inhibitor of acetylcholinesterase (AChEI) licensed for the treatment of Alzheimer disease (AD); and is the first and only AChEI licensed for the treatment of severe AD. Its efficacy as monotherapy, or in combination with...

  • Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX. Karasova, Jana Zdarova; Bajgar, Jiri; Novotny, Ladislav; Kuca, Kamil // Letters in Drug Design & Discovery;Dec2009, Vol. 6 Issue 8, p563 

    Organophosphate nerve agents are still considered as potential threats in both military and terrorism situations. They are potent irreversible inhibitors of acetylcholinesterase in central and also in peripheral compartment. Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the...

  • Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec. Robinson, Jennifer D.; Neumiller, Joshua J.; Keith Campbell, R. // Drugs;2012, Vol. 72 Issue 18, p2319 

    The basal-bolus concept of delivering insulin to diabetic patients makes physiological sense, as it mimics normal insulin release in people without diabetes. In line with this concept, a major effort put forth by insulin manufacturers has been to develop the ideal exogenous basal insulin...

  • Niacin Revisited: A Randomized, Controlled Trial of Wax-Matrix Sustained-Release Niacin in Hypercholesterolemia.  // JAMA: Journal of the American Medical Association;10/23/91-10/30/91, Vol. 266 Issue 16, p2209 

    Discusses the abstract of the article 'Niacin Revisited: A Randomized, Controlled Trial of Wax-Matrix Sustained-Released Niacin in Hypercholesterolemia,' by Joseph M. Keenan et al., published in a 1991 issue of the 'Archives of Internal Medicine' journal.

  • Debiopharm offers encouraging data for Alzheimer's treatment.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p7 

    No abstract available.

  • CLINIC ROUNDUP.  // BioWorld Today;4/29/2008, Vol. 19 Issue 83, p4 

    This section offers news briefs on clinical trials as of April 29, 2008. Cara Therapeutics Inc. has begun a Phase I clinical trial of its long-acting peripheral kappa opioid receptor agonist, CR845. The first dosing regime in a Phase I study of the HuCAL-derived antibody MOR103 has been...

  • Other News To Note.  // BioWorld International;8/29/2012, Vol. 17 Issue 35, p2 

    This section offers news briefs related to clinical trials as of August 2012. Phase I pharmacokinetic data for ActoGeniX's AG013 oral rinsing solution for the prevention of oral mucositis has showed that the liver AG013 bacteria adhered to the buccal mucosa and secreted protein locally. A Phase...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics